Abbott India Past Earnings Performance
Past criteria checks 5/6
Abbott India has been growing earnings at an average annual rate of 17.4%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 9.4% per year. Abbott India's return on equity is 36.8%, and it has net margins of 19.9%.
Key information
17.4%
Earnings growth rate
17.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.4% |
| Return on equity | 36.8% |
| Net Margin | 19.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Abbott India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 57,534 | 11,456 | 6,799 | 0 |
| 30 Sep 23 | 56,384 | 10,814 | 6,760 | 0 |
| 30 Jun 23 | 55,236 | 10,340 | 6,828 | 0 |
| 31 Mar 23 | 53,487 | 9,494 | 6,855 | 0 |
| 31 Dec 22 | 52,654 | 9,294 | 7,285 | 0 |
| 30 Sep 22 | 51,632 | 8,818 | 7,348 | 0 |
| 30 Jun 22 | 50,058 | 8,086 | 7,422 | 0 |
| 31 Mar 22 | 49,133 | 7,987 | 7,356 | 0 |
| 31 Dec 21 | 47,598 | 7,398 | 6,852 | 0 |
| 30 Sep 21 | 46,308 | 7,177 | 6,632 | 0 |
| 30 Jun 21 | 44,636 | 7,061 | 6,296 | 0 |
| 31 Mar 21 | 43,100 | 6,907 | 6,126 | 0 |
| 31 Dec 20 | 41,757 | 6,492 | 6,345 | 0 |
| 30 Sep 20 | 41,586 | 6,587 | 6,339 | 0 |
| 30 Jun 20 | 41,585 | 6,563 | 4,844 | 0 |
| 31 Mar 20 | 40,931 | 5,929 | 6,227 | 0 |
| 31 Dec 19 | 40,383 | 5,952 | 6,357 | 0 |
| 30 Sep 19 | 39,077 | 5,255 | 6,231 | 0 |
| 30 Jun 19 | 38,326 | 4,849 | 6,076 | 0 |
| 31 Mar 19 | 36,786 | 4,503 | 6,022 | 0 |
| 31 Dec 18 | 35,606 | 4,372 | 5,727 | 0 |
| 30 Sep 18 | 34,941 | 4,355 | 5,575 | 0 |
| 30 Jun 18 | 34,460 | 4,354 | 5,506 | 0 |
| 31 Mar 18 | 32,985 | 4,012 | 5,325 | 0 |
| 31 Dec 17 | 32,242 | 3,432 | 4,760 | 0 |
| 30 Sep 17 | 30,893 | 3,134 | 4,727 | 0 |
| 30 Jun 17 | 28,794 | 2,509 | 4,613 | 0 |
| 31 Mar 17 | 29,026 | 2,766 | 4,517 | 0 |
| 31 Dec 16 | 28,959 | 2,980 | 4,402 | 0 |
| 30 Sep 16 | 28,097 | 2,802 | 4,403 | 0 |
| 30 Jun 16 | 27,293 | 2,663 | 4,403 | 0 |
| 31 Mar 16 | 26,145 | 2,553 | 4,444 | 0 |
| 31 Dec 15 | 25,380 | 2,504 | 6,194 | 0 |
| 30 Sep 15 | 24,504 | 2,445 | 6,109 | 0 |
| 30 Jun 15 | 23,950 | 2,466 | 6,016 | 0 |
| 31 Mar 15 | 22,893 | 2,290 | 4,002 | 0 |
| 31 Dec 14 | 22,008 | 2,176 | 5,943 | 0 |
| 30 Sep 14 | 21,103 | 2,065 | 5,706 | 0 |
| 30 Jun 14 | 19,776 | 1,880 | 5,558 | 0 |
| 31 Mar 14 | 18,694 | 1,668 | 5,541 | 0 |
| 31 Dec 13 | 17,527 | 1,601 | 2,313 | 0 |
| 30 Sep 13 | 17,580 | 1,273 | 4,297 | 0 |
| 30 Jun 13 | 17,196 | 1,495 | 4,249 | 0 |
Quality Earnings: 500488 has high quality earnings.
Growing Profit Margin: 500488's current net profit margins (19.9%) are higher than last year (17.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500488's earnings have grown by 17.4% per year over the past 5 years.
Accelerating Growth: 500488's earnings growth over the past year (23.3%) exceeds its 5-year average (17.4% per year).
Earnings vs Industry: 500488 earnings growth over the past year (23.3%) did not outperform the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 500488's Return on Equity (36.8%) is considered high.